8-K: Regen Biopharma Secures $130,000 Through Highly Dilutive Convertible Note

Regen Biopharma, Inc. has entered into a securities purchase agreement with CFI Capital LLC for a $130,000 convertible promissory note, providing $117,000 in immediate funding under terms highly unfavorable to existing shareholders.

Summary

• Regen Biopharma, Inc. secured $130,000 in financing through a 6% convertible promissory note with CFI Capital LLC.
• The company received $117,000 in cash, with $13,000 retained by CFI Capital LLC as an Original Issue Discount.
• The Note matures on July 28, 2026, and bears interest at 6% per annum, payable in common stock.
• CFI Capital LLC can convert the principal and accrued interest into common stock at any time after January 28, 2026.
• The conversion price is set at 60% of the lowest trading price of the Common Stock over the twenty prior trading days, including the day of conversion notice.
• The conversion price discount increases to 50% if the company's shares experience a DTC Chill.
• The company must reserve 15,700,485 shares for conversions and maintain a reserve of at least five times the amount of shares required for full conversion.
• Significant prepayment penalties apply, ranging from 105% to 140% of principal plus accrued interest.
• The agreement includes extensive default provisions, triggering immediate acceleration and increased conversion discounts (to 45%) and daily penalties for certain breaches like failure to deliver shares.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the highly dilutive and predatory nature of the convertible note terms. The significant discount, floating conversion price, interest payable in stock, and severe default penalties indicate a desperate need for capital and a financing structure that heavily favors the lender at the expense of existing shareholders. This type of financing often leads to substantial share price depreciation and extreme dilution.

Positives

• Secured $117,000 in immediate funding to support operations.

Negatives

• The $13,000 Original Issue Discount means the company received only $117,000 for a $130,000 note, effectively increasing the cost of capital.
• The conversion price of 60% of the lowest trading price over 20 days is highly dilutive and unfavorable to existing shareholders, as it encourages conversion at depressed prices.
• Interest is payable in common stock, leading to further dilution.
• The significant prepayment penalties (up to 140%) make early repayment very costly, locking the company into the unfavorable terms.
• The extensive list of Events of Default and severe penalties (e.g., conversion price dropping to 45%, daily penalties for non-delivery of shares) indicate a high-risk financing arrangement for the company.
• The requirement to maintain a share reserve of five times the amount needed for full conversion, and to increase authorized capital if unable to do so, suggests potential for massive future dilution.

Risks

• Significant Share Dilution: The conversion terms (60% of lowest 20-day trading price, interest payable in stock) pose a substantial risk of future dilution for existing shareholders.
• Death Spiral Financing: The floating conversion price tied to the lowest trading price can create a 'death spiral' where conversions drive down the stock price, leading to more conversions at lower prices.
• DTC Chill Impact: A DTC Chill would further reduce the conversion price to 50%, exacerbating dilution.
• Inability to Maintain Share Reserve: Failure to maintain the required share reserve (five times the full conversion amount) is an Event of Default, potentially forcing the company to increase authorized capital, leading to further dilution.
• Default Penalties: The severe penalties for various defaults, including a reduction in conversion price to 45% and daily monetary penalties for non-delivery of shares, could quickly cripple the company financially.
• Liquidity Risk: The company's ability to repay the note or manage conversions without severe stock price impact is a significant concern given the terms.
• Regulatory Compliance Risk: Failure to file periodic reports with the SEC is an Event of Default, which could lead to further penalties and investor distrust.
• Delisting Risk: Delisting from an exchange or suspension of trading for more than 10 consecutive days is an Event of Default.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the terms of the convertible note itself, which implies a future need for capital or a strategy to manage the potential dilution from conversions.

Management Comments

• The filing includes the signature of David Koos, CEO, but does not contain any notable quotes or paraphrased statements from management regarding the transaction or company strategy.

Industry Context

Small biotechnology and biopharma companies, especially those in early development stages like Regen Biopharma, often face challenges in securing traditional equity or debt financing due to high risk and lack of immediate revenue. Convertible notes, particularly those with significant discounts and floating conversion prices, are a common but often highly dilutive financing mechanism used by companies with limited alternatives. This type of financing is typically sought when a company needs capital quickly and traditional funding sources are unavailable or too expensive, often signaling financial distress or a critical need to fund ongoing research and development.

Comparison to Industry Standards

• This convertible note, with its 60% conversion price discount to the lowest trading price over 20 days, is significantly more aggressive and dilutive than standard convertible debt instruments typically seen in more mature or stable industries.
• While such terms are not uncommon for micro-cap or distressed biotech companies, they are generally considered highly unfavorable to existing shareholders.
• A typical convertible note might have a fixed conversion price or a smaller discount to the current market price, rather than a floating discount tied to the lowest recent trading price.
• The extensive list of default provisions and severe penalties, including further conversion price reductions and daily fines, also indicates terms heavily skewed in favor of the lender (CFI Capital LLC), reflecting the high perceived risk of lending to Regen Biopharma.
• Comparable companies in similar financial positions might also resort to such financing, but it is generally viewed as a last resort due to its potential for extreme dilution and stock price pressure.

Stakeholder Impact

• Shareholders: Highly negative impact due to significant potential for dilution from the convertible note's terms (60% discount to lowest trading price, interest paid in stock, potential for further discount upon DTC Chill or default). This type of financing often leads to substantial share price depreciation.
• Creditors: CFI Capital LLC, as the note holder, benefits from highly favorable terms, including a significant discount on conversion, high prepayment penalties, and strong protections via extensive default clauses and remedies.
• Employees: Indirect impact from potential financial instability or stock price decline, which could affect stock-based compensation or overall company morale.

Next Steps

• The company will need to manage the potential conversion of the note into common stock, which could lead to significant dilution.
• The company must ensure it maintains the required share reserve for conversions and potentially increase its authorized capital if necessary.
• The company must avoid any Events of Default, as the penalties are severe.
• The company will need to make interest payments in common stock or repay the principal by July 28, 2026.

Key Dates

Recommendation

This financing arrangement is highly detrimental to existing shareholders. The terms of the convertible note, particularly the 60% conversion discount to the lowest trading price over 20 days, the interest payable in stock, and the severe penalties for default, are indicative of a 'death spiral' financing. This structure incentivizes the lender to convert shares at ever-lower prices, leading to massive dilution and significant downward pressure on the stock price. The company's acceptance of such unfavorable terms suggests a desperate need for capital and a lack of better financing alternatives, signaling severe underlying financial weakness. Investors should consider selling to avoid substantial future dilution and potential loss of capital.

Keywords

Regen Biopharma, Convertible Note, CFI Capital LLC, Dilution, Biopharma, Financing, SEC Filing, 8-K, Promissory Note, OTC Markets, Share Dilution, Death Spiral Financing, Biotechnology